<DOC>
	<DOCNO>NCT00002638</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat child relapse acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Children With Relapsed Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy autologous peripheral blood stem cell ( PBSC ) transplantation marrow reconstitution high-dose carmustine , cytarabine , etoposide , cyclophosphamide child relapse acute lymphocytic leukemia . - Determine dose effect autologous PBSC engraftment patient population . OUTLINE : Patients receive chemotherapy mobilization comprise cytarabine IV every 12 hour day 1-5 . When blood count recover , autologous peripheral blood stem cell ( PBSC ) harvest select mononuclear cell , granulocyte-macrophage colony-forming unit , CD34+ cell . Patients receive preparative regimen comprise carmustine IV day -8 -3 , cytarabine IV every 12 hour etoposide IV every 12 hour day -7 -4 , cyclophosphamide IV day -2 -1 . PBSC reinfused day 0 . Patients receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) begin PBSC transplantation . Male patient undergo radiotherapy testes transplantation . Patients history CNS leukemia undergo craniospinal irradiation transplantation . Patients follow 100 day , 6 month , 1 year . PROJECTED ACCRUAL : Approximately 30 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoblastic leukemia Pathologic evidence relapse marrow , CNS , testes In second late complete remission Ineligible allogeneic transplantation : No suitable allogeneic donor ( sibling family donor unrelated donor 1 HLAA B antigen mismatch HLADR identical ) OR Ineligible preparative regimen include totalbody irradiation Peripheral blood stem cell collection feasible : Patient size generally least 8 kg Able place central venous catheter Patient cooperative PATIENT CHARACTERISTICS : Age : 1 19 Performance status : Not moribund Life expectancy : No severe limit disease leukemia Hepatic : Bilirubin great 3 time normal age AST and/or GGT great 3 time normal age No evidence hepatic synthetic dysfunction Renal : GFR least 50 % normal base Glofil study 12hour creatinine clearance Cardiovascular : Cardiac contractility normal echocardiogram Pulmonary : FVC FEV_1 without DLCO least 50 % predict Other : No significant active infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
</DOC>